New perspectives in glutamate and anxiety
- PMID: 21569789
- DOI: 10.1016/j.pbb.2011.04.010
New perspectives in glutamate and anxiety
Abstract
Anxiety and stress-related disorders, namely posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), obsessive-compulsive disorder (ODC), social and specific phobias, and panic disorder, are a major public health issue. A growing body of evidence suggests that glutamatergic neurotransmission may be involved in the biological mechanisms underlying stress response and anxiety-related disorders. The glutamatergic system mediates the acquisition and extinction of fear-conditioning. Thus, new drugs targeting glutamatergic neurotransmission may be promising candidates for new pharmacological treatments. In particular, N-methyl-d-aspartate receptors (NMDAR) antagonists (AP5, AP7, CGP37849, CGP39551, LY235959, NPC17742, and MK-801), NMDAR partial agonists (DCS, ACPC), α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate receptors (AMPARs) antagonists (topiramate), and several allosteric modulators targeting metabotropic glutamate receptors (mGluRs) mGluR1, mGluR2/3, and mGluR5, have shown anxiolytic-like effects in several animal and human studies. Several studies have suggested that polyamines (agmatine, putrescine, spermidine, and spermine) may be involved in the neurobiological mechanisms underlying stress-response and anxiety-related disorders. This could mainly be attributed to their ability to modulate ionotropic glutamate receptors, especially NR2B subunits. The aim of this review is to establish that glutamate neurotransmission and polyaminergic system play a fundamental role in the onset of anxiety-related disorders. This may open the way for new drugs that may help to treat these conditions.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models.Pharmacol Biochem Behav. 2012 Feb;100(4):775-800. doi: 10.1016/j.pbb.2011.06.014. Epub 2011 Jun 25. Pharmacol Biochem Behav. 2012. PMID: 21708184 Review.
-
Polyaminergic agents modulate contextual fear extinction in rats.Neurobiol Learn Mem. 2010 May;93(4):589-95. doi: 10.1016/j.nlm.2010.02.007. Epub 2010 Mar 3. Neurobiol Learn Mem. 2010. PMID: 20206278
-
Glutamate and anxiety.Eur Neuropsychopharmacol. 2004 May;14(3):175-83. doi: 10.1016/S0924-977X(03)00100-7. Eur Neuropsychopharmacol. 2004. PMID: 15056476 Review.
-
The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?Eur J Pharmacol. 2014 Jan 15;723:181-4. doi: 10.1016/j.ejphar.2013.12.019. Epub 2013 Dec 18. Eur J Pharmacol. 2014. PMID: 24361306 Review.
-
Gender specific influence of endogenous glutamate release on stress-induced fear in rats.Endocr Regul. 2011 Jan;45(1):13-21. Endocr Regul. 2011. PMID: 21314206
Cited by
-
Exploring the interplay of chronic toxoplasmosis and NMDAR dysfunction: Insights into schizophrenia-like behaviors and therapeutic potential.Open Vet J. 2024 Jul;14(7):1634-1643. doi: 10.5455/OVJ.2024.v14.i7.13. Epub 2024 Jul 31. Open Vet J. 2024. PMID: 39175964 Free PMC article.
-
NMDA Receptor Antagonists: Emerging Insights into Molecular Mechanisms and Clinical Applications in Neurological Disorders.Pharmaceuticals (Basel). 2024 May 15;17(5):639. doi: 10.3390/ph17050639. Pharmaceuticals (Basel). 2024. PMID: 38794209 Free PMC article. Review.
-
Association of Blood Metabolomics Biomarkers with Brain Metabolites and Patient-Reported Outcomes as a New Approach in Individualized Diagnosis of Schizophrenia.Int J Mol Sci. 2024 Feb 15;25(4):2294. doi: 10.3390/ijms25042294. Int J Mol Sci. 2024. PMID: 38396971 Free PMC article.
-
Discrimination exposure impacts unhealthy processing of food cues: crosstalk between the brain and gut.Nat Ment Health. 2023 Nov;1(11):841-852. doi: 10.1038/s44220-023-00134-9. Epub 2023 Oct 2. Nat Ment Health. 2023. PMID: 38094040 Free PMC article.
-
Brainwide Mendelian Randomization Study of Anxiety Disorders and Symptoms.Biol Psychiatry. 2024 Apr 15;95(8):810-817. doi: 10.1016/j.biopsych.2023.11.006. Epub 2023 Nov 14. Biol Psychiatry. 2024. PMID: 37967698
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials